TME Pharma N.V. (0N6A.F)
- Business Wire
TME Pharma Announces Results of Successful Capital Increase With €2.35 Million Raised
BERLIN, June 18, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that it has successfully completed a capital raise for a total consideration of €2.35 million gross through a private placement with professional investors and a public offering to retail investors in France via the PrimaryBid platfor
- Business Wire
TME Pharma Announces a Financing Guarantee Agreement and the Launch of Capital Increase of Minimum 2.2 Million Euros
BERLIN, June 17, 2024--Regulatory News: This information is only intended for residents of France and not intended for residents of other countries including the Netherlands and other EU/EEA Member States, the United Kingdom, United States, Australia, Canada or Japan. The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform thems
- Business Wire
TME Pharma Announces Publication in Nature Communications of Biomarker Data From NOX-A12 Gloria Phase 1/2 Trial in Glioblastoma
BERLIN, June 17, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of biomarker data from the GLORIA Phase 1/2 clinical trial of NOX-A12 in brain cancer (glioblastoma) in the peer-reviewed scientific journal Nature Communications.
